Equities

Viridian Therapeutics Inc

Viridian Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)20.04
  • Today's Change0.42 / 2.14%
  • Shares traded386.17k
  • 1 Year change+27.81%
  • Beta1.0570
Data delayed at least 15 minutes, as of Nov 22 2024 18:58 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy7
Outperform8
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 16 analysts offering 12 month price targets for Viridian Therapeutics Inc have a median target of 41.00, with a high estimate of 61.00 and a low estimate of 22.00. The median estimate represents a 108.97% increase from the last price of 19.62.
High210.9%61.00
Med109.0%41.00
Low12.1%22.00

Earnings history & estimates in USD

On Nov 12, 2024, Viridian Therapeutics Inc reported 3rd quarter 2024 losses of -1.15 per share.
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate-6.06%
Viridian Therapeutics Inc reported annual 2023 losses of -5.31 per share on Feb 27, 2024.
Average growth rate+23.24%
More ▼

Revenue history & estimates in USD

Miragen Therapeutics had 3rd quarter 2024 revenues of 86.00k. This bettered the 46.00k consensus of the 13 analysts covering the company. This was 12.24% below the prior year's 3rd quarter results.
Average growth rate+4.86%
Miragen Therapeutics had revenues for the full year 2023 of 314.00k. This was 82.28% below the prior year's results.
Average growth rate-4.19%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.